Pharmacological Insights: Mitochondrial ROS Generation by FNC (Azvudine) in Dalton’s Lymphoma Cells Revealed by Super Resolution Imaging

• DOI: 10.1007/s12013-024-01238-4
• Publication Date: 2024-03-14T09:05:39Z
• Authors: Naveen Kumar; Vikram Delu; Ilya Ulasov; Sanjay Kumar; Rishi Kant Singh; Sandeep Kumar; Alok Shukla; Anand Kumar Patel; Lokesh Yadav; Ruchi Tiwari; Kumari Rachana; Shivashish Priyad...; Varsha Singh; Anuradha Yadav; Kaushalendra Kaus...; Arbind Acharya
• Keywords: Viability assay; Mitochondrial ROS

Nucleoside analogs are a common form of chemotherapy that disrupts DNA replication and repair, leading to cell cycle arrest and apoptosis. Reactive oxygen species (ROS) production is a significant mechanism through which these drugs exert their anticancer effects. This study investigated a new nucleoside analog called FNC or Azvudine, and its impact on ROS production and cell viability in Dalton's lymphoma (DL) cells. The study found that FNC treatment resulted in a time- and dose-dependent increase in ROS levels in DL cells. After 15 and 30 min of treatment with 2 and 1 mg/ml of FNC, mitochondrial ROS production was observed in DL cells. Furthermore, prolonged exposure to FNC caused structural alterations and DNA damage in DL cells. The results suggest that FNC's ability to impair DL cell viability may be due to its induction of ROS production and indicate a need for further investigation.